Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023

On March 16, 2023 Philogen reported that it will attend AACR (Free AACR Whitepaper) Annual Meeting in Orlando on April 14-18, 2023 (Press release, Philogen, MAR 16, 2023, View Source [SID1234628939]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Matilde Bocci, Eleonora Prodi, Sara Puglioli, Giulia Rotta and Aureliano Zana will participate at the event.

Moreover, the following abstracts have been accepted as Poster Presentations:

Dr. Galbiati – Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics

Eleonora Prodi – Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF)

Matilde Bocci – Delivery of cytotoxic camptothecin derivatives to tumors by OncoFAP-based Small Molecule-Drug Conjugates

Sara Puglioli – DNA-encoded affinity maturation libraries enable the discovery of low picomolar Fibroblast Activation Protein inhibitors suitable for radioligand therapy of solid tumors

Aureliano Zana – FAP-targeted non-internalizing drug conjugates: a comparative evaluation between small molecules, antibodies and peptides

Giulia Rotta – Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation.